Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT-2: Sintilimab in Advanced Esophageal Squamous Cell Carcinoma
NCT03116152Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- May 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Innovent Biologics. Started May 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03116152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116152.